OncoSec Medical Inc (ONCSQ)

[chickpea598]

Oncosec has indicated that front-line therapy is where this will be headed. The need to treat patients at an earlier stage of their disease with TAVO would obviously be the wise choice when patients have a stronger immune sytsem. This is what should have been done in the first place; a head to head study with two arms of patients, one with just Keytruda vs. a second arm with TAVO + Keytuda. The planned trial with Opdivo would be a front-line indication (neoadjuvant setting).